Facebook
Twitter
LinkedIn
ForwardBrain Metastases Radiotherapy while Mitigating Radionecrosis and Neurotoxicity (PRO 02)
This activity is divided into 3 subsections:
1) Updates on brain met management: Discussion of selecting patients for HA-WBRT and SRS including a good amount of dialogue on developing concepts in pre- and post-op radiosurgery (who to consider for what sequence, dose and planning considerations).
2) Neurocognitive preservation: What does it actually mean to patients (tips on counseling, any supportive resources), differences with SRS vs. whole brain, memantine (role, considerations when prescribing, taper), hippocampal avoidance (how to and planning), role for additional substructure sparing.
3) Radionecrosis: Prevention strategies for intact brain mets (dose/fraction, technique/platform considerations, composite dosing or serial treatment days), diagnosis tools (PET, rCBV), and management (Avastin, LITT, excision, etc).
Target Audience
This activity is designed to meet the interests of radiation oncologists, surgeons, nurses, radiation dosimetrists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Develop a framework for selecting the optimal treatment for patients with brain metastases.
- Increase the tools for diagnosis and management of radionecrosis.
- Better counsel patients on risk of neurotoxicity and options for mitigating and managing the toxicity.
- Avani Dholakia Rao, MD, is employed by Radiation Oncology Associates of the National Capital Region.
- Stuart H. Burri, MD, is employed by Southeast Radiation Oncology Group.
- William Breen, MD, is employed by the Mayo Clinic.
- Raj Singh, MD, is employed by The Ohio State University Wexner Medical Center.
- Beant Singh Gill, MD, is employed by Associates in Radiation Medicine.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Meeting Steering Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.